Table 1.
Study | Age | Patients | Treatment | Dosing regimen | Median OS (months) |
---|---|---|---|---|---|
Nordic Malmstrom et al. [20] |
≥ 60 | 291 | TMZ | 5/28 days | 8.3 |
hRT | 34 Gy | 7.5 | |||
RT | 60 Gy | 6.0 | |||
> 70 | 123 | TMZ | 5/28 days | 9.0 | |
RT | 34 Gy | 7.0 | |||
RT | 60 Gy | 5.2 | |||
NOA-08 Wick et al. [19] |
> 65 | 373 | RT | 60 Gy | 9.6 |
TMZ | 7 days on, 7 days off | 8.6 | |||
CCTG/EORTC 26062 Perry et al. [64] |
> 65 | 562 | RT+TMZ | 60 Gy | 5.3 |
RT+TMZ | 40 Gy | 9.3 | |||
ANOCEF trial Keime-Guibert et al. [50] |
≥ 70 | 85 | RT | 50 Gy | 6.7 |
Supportive care | 3.9 |
NOA Neurooncology Working Group; Canadian Cancer Trials Group (CCTG); EORTC European Organisation for Research and Treatment of Cancer (EORTC); ANOCEF The Association des Neuro-Oncologues d’Expression Française; TMZ temozolomide; hRT hypofractionated radiation therapy